1. Home
  2. CXAI vs CALC Comparison

CXAI vs CALC Comparison

Compare CXAI & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CXApp Inc.

CXAI

CXApp Inc.

HOLD

Current Price

$0.34

Market Cap

17.8M

Sector

Technology

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$6.02

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXAI
CALC
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
88.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CXAI
CALC
Price
$0.34
$6.02
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
2.9M
83.4K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,222,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$70.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$1.42
52 Week High
$2.54
$6.40

Technical Indicators

Market Signals
Indicator
CXAI
CALC
Relative Strength Index (RSI) 35.44 68.87
Support Level $0.32 $5.90
Resistance Level $0.41 $6.40
Average True Range (ATR) 0.06 0.59
MACD 0.00 0.13
Stochastic Oscillator 3.86 64.63

Price Performance

Historical Comparison
CXAI
CALC

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: